Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT05686642

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05686642
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05686642. Randomized; double masking; primary purpose treatment. Start 2023-04-06 (actual); primary completion 2026-12-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
LT3001 Drug:high dose
Intervention (Drug)
Placebo
Intervention (Drug)
LT3001 Drug:low dose
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct05686642
Content hash
45ab588b3e7adade3f499c35fb46b20aa429a868407149c05685a729831ac620